| This week's sponsor is Premier Research. | |  | Immunotherapy: Unleashing the Body's Potential to Fight Cancer
The immune system's role in fighting cancer becomes clearer every day, and the therapeutic implications are enormous. Discover promising new approaches to immunotherapy in our new white paper.
Premier Research. It's what we do. Best. |
Featured Story | | | Wednesday, June 21, 2017 The FDA is working on a medical innovation development plan designed to lower healthcare costs by streamlining the path to market for targeted therapies and other novel drugs. Commissioner Scott Gottlieb, M.D., pitched the plan as a broad drive to ensure the FDA has the tools and policies to encourage and evaluate innovative therapies. |
|
|
| This week's sponsor is Myriad RBM. | |  | |
Top Stories Wednesday, June 21, 2017 ImmunoCellular Therapeutics has been forced to suspend a phase 3 trial of its lead cancer vaccine, ICT-107, after failing to raise the funds it needs to complete the study. Tuesday, June 20, 2017 Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic. The Flagship Pioneering-backed biotech is using its method for expressing proteins on allogeneic red blood cells to create candidates that hit multiple immuno-oncology targets. Monday, June 19, 2017 How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development Wednesday, June 21, 2017 New York biotech Syntimmune has got off a beefy $50 million series B round as it looks to use the funds for its FcRn biology tests. Wednesday, June 21, 2017 Sarepta Therapeutics has penned its second DMD gene therapy pact this year as it announces a tie-up with France’s Genethon, a nonprofit R&D org. Tuesday, June 20, 2017 SerImmune, whose technology maps the human antibody repertoire, rounded up $8 million from Merck, Illumina Ventures and unnamed investors. The funds will drive the expansion of the company’s immune mapping platform and antibody repertoire database. Tuesday, June 20, 2017 Microbiome startup AOBiome first tapped Veristat to help run a phase 2 study that tests its ammonia-oxidizing bacteria for the treatment of hypertension, and after Veristat finished enrollment earlier than expected, AOBiome decided to extend the collaboration. Wednesday, June 21, 2017 IBM and Baheal Pharmaceutical have moved quickly to expand their relationship. Weeks after IBM gave Baheal a starring role in selling its Watson for Oncology product in China, Big Blue has penned a similar deal covering its molecular data interpretation technology. | This week's sponsor is J.P. Morgan Private Bank. | |  | How Your Assets Are Structured Can Have Long-Term Implications On Your Wealth
As a founder or executive of a healthcare business, it's crucial your assets are titled properly. J.P. Morgan Private Bank knows how to protect your assets and preserve your wealth. Download this article on asset ownership to learn more. |
| | | Eisai says its study of lorcaserin will "continue as planned" after the DMC signed off on an interim safety review of the trial. Statement Blood disease biotech Tolero Pharmaceuticals says it is adding European study centers to its ongoing midstage test for alvocidib in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Release | |
|
Resources Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Presented by: Veeva Hear three innovative leaders explain how regulatory can “go digital” in their operations by leveraging the data-handling capabilities in their RIM systems. Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. | 
